H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on KRYS stock, giving a Buy rating on February 11.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Pantginis has given his Buy rating due to a combination of factors that reflect Krystal Biotech’s robust financial performance and strategic growth initiatives. Despite minor discrepancies between actual earnings and projections, Krystal ended 2024 with a strong financial position, boasting significant revenue from VYJUVEK, which has surpassed expectations since its approval. The company’s ability to secure numerous reimbursement approvals across the nation and its strategic plan to expand into European and Japanese markets further bolster its growth prospects.
Additionally, Krystal’s burgeoning gene therapy pipeline offers promising advancements, with multiple clinical trials progressing across various therapeutic areas. The development of treatments for conditions such as cystic fibrosis, alpha-1 antitrypsin deficiency, and DEB, among others, signifies a strong trajectory for future breakthroughs. These elements, combined with Krystal’s strategic global expansion efforts and ongoing clinical developments, underpin Pantginis’s optimistic outlook and the Buy rating for the stock.
In another report released on February 11, Bank of America Securities also reiterated a Buy rating on the stock with a $196.00 price target.